Primary and official source record
This hub separates peer-reviewed precedent, official guidance and comparable facilities from VARUNÉ's own current position. It informs concept design for Glasgow and Hyderabad; it does not establish a site, partnership, operating capability, licence, approval or performance result.
Founder + company funding evidence
The ledger distinguishes public records, the signed SMART:SCOTLAND award record and £43,000 in secured private non-dilutive match funding. It also separates NEUVIOR's execution track record from any future capital package for VARUNÉ Labs.
Three awarded programmes plus £43,000 in secured private non-dilutive match funding
Innovate UK
Public UKRI Gateway to Research record.
Open the UKRI organisation recordInnovate UK
Public UKRI Gateway to Research record.
Open the UKRI organisation recordScottish Enterprise SMART:SCOTLAND · project 2025_00003995
Signed offer accepted on 14 April 2026; signed eligible project budget £144,020.53.
Read public award coveragePrivate non-dilutive match funding
Private funding and match-funding record held by NEUVIOR.
How to read this record
Every source below is primary, peer-reviewed or published by the responsible institution, regulator or government. Its limits travel with it.
An official page describing another organisation's facilities or services. It does not establish a VARUNÉ partnership, access route or equivalent capability.
A peer-reviewed study showing what a defined research system achieved. Its result belongs to that study and should not be transferred to VARUNÉ.
Official guidance, rules or policy that can shape future requirements. A citation is not evidence of compliance, approval, funding or endorsement.
A design or diligence question informed by the source. It remains proposed until demand, site, operator, finance and permissions are evidenced.
Comparator facilities
These official records show relevant capabilities or shared infrastructure models elsewhere. They are comparators, not VARUNÉ partners, appointed providers or evidence that equivalent facilities exist within either proposed campus.
CPI describes a Glasgow region centre for medicines process innovation, including advanced analytics, continuous direct compression, modular processing and digital twin development.
Campus implication. Useful precedent for asking which formulation, process and digital capabilities should remain external, be shared or justify later ownership. CPI is not represented as a VARUNÉ partner or provider.
CMAC's official equipment record spans analytical and solid-state characterisation, drug product development, crystallisation, process analytical technology, automation and digital systems.
Campus implication. A relevant benchmark for equipment selection, connected workflows and partner-first access. It does not evidence reserved access, collaboration or installed VARUNÉ equipment.
The University of Glasgow describes genomics, proteomics and metabolomics services with experimental design, quality control and data analysis support.
Campus implication. Supports testing a partner-led translational route before considering specialised internal capability. No relationship, access or project is represented.
The National Manufacturing Institute Scotland describes a process manufacturing environment for evaluating artificial intelligence, robotics, digital data and immersive technologies.
Campus implication. A comparator for testing bounded automation and digital process questions in a lower-risk setting. It is not evidence of pharmaceutical validation or a VARUNÉ relationship.
India's Department of Pharmaceuticals records NIPER Hyderabad activity in pharmaceutical analysis, pharmaceutics, biotechnology, regulatory affairs, pharmacoinformatics and process chemistry.
Campus implication. Supports the regional skills and research context only. It does not establish collaboration, facility access, capacity or endorsement for VARUNÉ.
The Department of Biotechnology describes shared pilot and precommercial infrastructure intended for start-ups, small and medium-sized enterprises, industry and academia.
Campus implication. A national comparator for governed shared access, scale-up and skills. Policy alignment is not an award, programme membership, funding decision or partnership.
Peer-reviewed precedent
The studies show that robots, instruments, models and human defined objectives can be connected in specific research workflows. They do not support claims of general autonomy, guaranteed performance, clinical success or GMP readiness.
A Nature Communications study connected digital formulation, robotic make and test workflows, near-infrared measurement, automated tablet testing and physics-informed Bayesian optimisation.
Campus implication. Supports the technical plausibility of a tightly bounded autonomous formulation cell. The reported speed and material savings belong to this study and do not describe VARUNÉ performance or GMP operation.
A Digital Discovery study used a liquid handling robot and Bayesian optimisation to explore a defined curcumin formulation space and identify lead formulations.
Campus implication. Supports measured, closed-loop screening as a research precedent. It is one non-GMP proof of concept, not evidence of universal productivity or an active VARUNÉ experiment.
A ChemMethods paper describes robotic mixing, titration and cleaning combined with physics informed machine learning for viscous formulations.
Campus implication. A useful automation method precedent, but the work is outside pharmaceutical GMP. It cannot support claims of autonomous medicines manufacture or regulatory readiness.
Quality and regulation
Quality risk, analytical purpose, data integrity, transfer and manufacturing permissions should shape the programme early. Compliance still depends on the actual operator, product, premises, systems, evidence and regulator.
ICH Q8, Q9, Q10, Q13 and Q14 address pharmaceutical development, quality risk management, pharmaceutical quality systems, continuous manufacturing and analytical procedure development.
Campus implication. These guidelines can shape intended use, risk, data and transfer questions from the start. Citing them does not make a design, laboratory, process or organisation compliant.
MHRA guidance explains that making or assembling human medicines in the United Kingdom generally requires the appropriate manufacturer licence and applicable GMP evidence.
Campus implication. Any Glasgow manufacturing route must remain a separately authorised future stage with a defined operator, product scope, qualified systems and inspection. No licence is represented as held.
MHRA guidance sets expectations for data governance across the pharmaceutical product life cycle and regulated GxP settings.
Campus implication. Supports early design of accountable records, access, audit trails, review, retention and change control. It does not validate a proposed digital system.
CDSCO publishes the Drugs Rules and Gazette notifications that include the Indian GMP framework for pharmaceutical quality systems, premises, plant and equipment.
Campus implication. A future Hyderabad manufacturing module would need the applicable operator, product scope, licence, qualification, validation and inspection route. The current concept is not represented as ready for GMP.
Measured sustainability
A credible route measures energy, water, solvent, material and waste intensity at the relevant experiment, process and building boundaries. Net zero, zero liquid discharge and certification claims require project-specific evidence.
A life-cycle and techno-economic assessment across seven industrial pharmaceutical processes found potential benefits from flow routes alongside process- and solvent-specific exceptions.
Campus implication. The campus should meter energy, water, solvents, materials and waste by experiment or batch. Continuous processing should not be described as inherently sustainable.
A life-cycle study of pharmaceutical research crystallisation identifies solvent production as a major impact and examines recovery against incineration.
Campus implication. Supports solvent inventories, miniaturisation, recovery assessment and disclosed life-cycle boundaries rather than unsupported zero-waste language.
The strategy covers operational energy, heat, water, waste, travel and supply chain action, with a long-term net-zero direction for NHS Scotland.
Campus implication. A useful design benchmark for Glasgow, not a VARUNÉ target or certification. Any campus claim needs a defined baseline, scopes, delivery plan and independent evidence.
Telangana's 2026 to 2030 life sciences policy refers to green and zero liquid discharge practices. India's 2031 to 2035 NDC sets national climate and energy directions.
Campus implication. These sources inform Hyderabad diligence only. They do not prove site utilities, water treatment, renewable supply, zero liquid discharge, net zero or 2040 alignment for VARUNÉ.
Campus implications
The evidence supports phased questions, not fixed commitments. Each route can advance, change scope, remain external or stop as site, demand, infrastructure, regulatory, operating and capital evidence develops.
First test a compact, non-GMP formulation, analytical and bounded automation route against real users, external alternatives and site evidence.
Keep specialist translational work partner-led until repeat demand, lawful materials, competent operation and economics support another decision.
Treat pilot processing and any future activity licensed by the MHRA as separate gates requiring an operator, qualified utilities, quality systems, finance and inspection.
Frame 2040 value as a possible contribution to UK CMC knowledge, skills and process transfer resilience, not a guaranteed supply or NHS outcome.
Test formulation, analytical development, stability and governed automation as the first internal capability, subject to site and operating evidence.
Use qualified partners for scale-up and specialist work while demand, transfer requirements and the local delivery model are established.
Treat a future general oral solid dose Schedule M manufacturing module as separately designed, qualified, licensed and inspected. It is not ready for GMP today.
Frame 2040 value as a possible contribution to India-based scale-up, method transfer, workforce and resilience, not government-backed sovereign infrastructure.
Current boundary
VARUNÉ Labs is not represented as operating the cited facilities, reproducing the published studies, holding a manufacturing licence, owning the equipment described or having secured access to any named organisation.
The present work is active predevelopment: evidence review, campus and infrastructure diligence, operating model design and exploratory dialogue. Planned capabilities remain subject to site, demand, agreements, a committed campus capital package, approvals and accountable delivery.